UBS Group’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $409M | Buy |
6,065,779
+1,715,820
| +39% | +$114M | 0.05% | 370 |
|
|
2026
Q1 | $273M | Buy |
4,349,959
+2,426,179
| +126% | +$169M | 0.04% | 471 |
|
|
2025
Q4 | $128M | Sell |
1,923,780
-1,032,342
| -35% | -$66.7M | 0.02% | 838 |
|
|
2025
Q3 | $199M | Buy |
2,956,122
+1,023,431
| +53% | +$81M | 0.03% | 589 |
|
|
2025
Q2 | $169M | Sell |
1,932,691
-61,819
| -3% | -$4.85M | 0.03% | 618 |
|
|
2025
Q1 | $136M | Buy |
1,994,510
+46,824
| +2% | +$3.82M | 0.03% | 720 |
|
|
2024
Q4 | $151M | Buy |
1,947,686
+535,372
| +38% | +$39.6M | 0.03% | 658 |
|
|
2024
Q3 | $94.7M | Buy |
1,412,314
+215,023
| +18% | +$17.7M | 0.02% | 754 |
|
|
2024
Q2 | $136M | Buy |
1,197,291
+84,628
| +8% | +$10.7M | 0.03% | 497 |
|
|
2024
Q1 | $154M | Buy |
1,112,663
+84,435
| +8% | +$10.6M | 0.04% | 453 |
|
|
2023
Q4 | $128M | Sell |
1,028,228
-45,110
| -4% | -$4.61M | 0.04% | 479 |
|
|
2023
Q3 | $100M | Buy |
1,073,338
+126,531
| +13% | +$14.3M | 0.03% | 501 |
|
|
2023
Q2 | $122M | Buy |
946,807
+335,383
| +55% | +$40.6M | 0.04% | 416 |
|
|
2023
Q1 | $71M | Sell |
611,424
-54,676
| -8% | -$6.12M | 0.03% | 605 |
|
|
2022
Q4 | $75.4M | Buy |
666,100
+317,190
| +91% | +$34.8M | 0.03% | 608 |
|
|
2022
Q3 | $28.1M | Sell |
348,910
-92,903
| -21% | -$7.87M | 0.01% | 1050 |
|
|
2022
Q2 | $32.9M | Sell |
441,813
-71,075
| -14% | -$6.49M | 0.01% | 1005 |
|
|
2022
Q1 | $65.6M | Sell |
512,888
-228,464
| -31% | -$25M | 0.02% | 705 |
|
|
2021
Q4 | $99.5M | Buy |
741,352
+27,532
| +4% | +$3.96M | 0.03% | 605 |
|
|
2021
Q3 | $97.6M | Buy |
713,820
+148,220
| +26% | +$18.7M | 0.03% | 543 |
|
|
2021
Q2 | $60.4M | Buy |
565,600
+59,180
| +12% | +$5.68M | 0.02% | 745 |
|
|
2021
Q1 | $45.5M | Sell |
506,420
-43,612
| -8% | -$4.09M | 0.02% | 890 |
|
|
2020
Q4 | $50.8M | Buy |
550,032
+121,308
| +28% | +$10.8M | 0.02% | 776 |
|
|
2020
Q3 | $44.2M | Buy |
428,724
+58,272
| +16% | +$6.09M | 0.02% | 706 |
|
|
2020
Q2 | $37.5M | Buy |
370,452
+25,140
| +7% | +$2.25M | 0.02% | 741 |
|
|
2020
Q1 | $23.2M | Buy |
345,312
+28,540
| +9% | +$1.78M | 0.01% | 908 |
|
|
2019
Q4 | $17.3M | Buy |
316,772
+64,856
| +26% | +$3.08M | 0.01% | 1479 |
|
|
2019
Q3 | $9.4M | Sell |
251,916
-119,712
| -32% | -$4.65M | ﹤0.01% | 1813 |
|
|
2019
Q2 | $13.9M | Sell |
371,628
-79,300
| -18% | -$2.49M | 0.01% | 1484 |
|
|
2019
Q1 | $13.4M | Buy |
450,928
+209,836
| +87% | +$7.37M | 0.01% | 1441 |
|
|
2018
Q4 | $7.22M | Buy |
241,092
+126,264
| +110% | +$4.01M | ﹤0.01% | 1852 |
|
|
2018
Q3 | $4.11M | Buy |
114,828
+41,252
| +56% | +$1.28M | ﹤0.01% | 2531 |
|
|
2018
Q2 | $1.75M | Buy |
73,576
+9,872
| +15% | +$209K | ﹤0.01% | 3289 |
|
|
2018
Q1 | $1.18M | Buy |
63,704
+27,560
| +76% | +$408K | ﹤0.01% | 3582 |
|
|
2017
Q4 | $519K | Sell |
36,144
-371,284
| -91% | -$4.83M | ﹤0.01% | 4267 |
|
|
2017
Q3 | $4.98M | Buy |
407,428
+332,136
| +441% | +$5.87M | ﹤0.01% | 2212 |
|
|
2017
Q2 | $1.38M | Sell |
75,292
-5,976
| -7% | -$110K | ﹤0.01% | 3344 |
|
|
2017
Q1 | $1.72M | Buy |
81,268
+8,152
| +11% | +$159K | ﹤0.01% | 3073 |
|
|
2016
Q4 | $1.09M | Sell |
73,116
-10,396
| -12% | -$184K | ﹤0.01% | 3476 |
|
|
2016
Q3 | $1.83M | Buy |
83,512
+12,224
| +17% | +$272K | ﹤0.01% | 2920 |
|
|
2016
Q2 | $1.41M | Buy |
71,288
+39,456
| +124% | +$672K | ﹤0.01% | 3076 |
|
|
2016
Q1 | $541K | Sell |
31,832
-77,280
| -71% | -$1.29M | ﹤0.01% | 3714 |
|
|
2015
Q4 | $2.23M | Sell |
109,112
-23,928
| -18% | -$498K | ﹤0.01% | 2688 |
|
|
2015
Q3 | $2.86M | Buy |
133,040
+37,576
| +39% | +$838K | ﹤0.01% | 2423 |
|
|
2015
Q2 | $1.91M | Buy |
95,464
+2,016
| +2% | +$35.4K | ﹤0.01% | 3025 |
|
|
2015
Q1 | $1.46M | Buy |
93,448
+28,408
| +44% | +$429K | ﹤0.01% | 3224 |
|
|
2014
Q4 | $895K | Buy |
+65,040
| New | +$796K | ﹤0.01% | 3662 |
|
Other funds holding DXCM
UBS Group's DXCM Position: Q2 2026 in Review
UBS Group increased its DexCom (DXCM) stake by 39% in Q2 2026, buying an estimated $114M and bringing the position to 6,065,779 shares worth $409M. The position accounts for 0.05% of the portfolio, ranked #370.
UBS Group first reported a position in DXCM in Q4 2014 and has held it in 47 quarters since. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- UBS Group held 6,065,779 shares of DexCom worth $409M as of Q2 2026.
- UBS Group bought 1,715,820 DexCom shares in Q2 2026, an estimated $114M.
- DexCom made up 0.05% of UBS Group's portfolio in Q2 2026, its #370 holding.
- UBS Group first reported a position in DexCom in Q4 2014 and has held it in 47 quarters since.
- 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.